Form 8-K - Current report:
SEC Accession No. 0001641172-25-005777
Filing Date
2025-04-23
Accepted
2025-04-23 08:10:13
Documents
18
Period of Report
2025-04-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 62069
2 ex10-1.htm EX-10.1 69583
3 ex10-2.htm EX-10.2 200919
4 ex99-1.htm EX-99.1 14571
5 ex10-2_001.jpg GRAPHIC 26333
  Complete submission text file 0001641172-25-005777.txt   677415

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cldi-20250417.xsd EX-101.SCH 3813
7 XBRL DEFINITION FILE cldi-20250417_def.xml EX-101.DEF 26683
8 XBRL LABEL FILE cldi-20250417_lab.xml EX-101.LAB 36817
9 XBRL PRESENTATION FILE cldi-20250417_pre.xml EX-101.PRE 25307
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5761
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 25859268
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)